Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

5.36
+0.24504.79%
Volume:1.67M
Turnover:8.84M
Market Cap:579.53M
PE:-2.66
High:5.45
Open:5.17
Low:5.10
Close:5.11
52wk High:8.91
52wk Low:2.19
Shares:108.22M
Float Shares:78.79M
Volume Ratio:1.57
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-2.0100
ROE:-60.27%
ROA:-33.29%
PB:2.09
PE(LYR):-2.66

Loading ...

Rocket Pharmaceuticals Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Nov 18, 2025

Cantor Fitzgerald Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Nov 07, 2025

Rocket Pharmaceuticals Q3 EPS $(0.45) Beats $(0.52) Estimate

Benzinga
·
Nov 07, 2025

Rocket Pharmaceuticals Q3 net loss narrows

Reuters
·
Nov 07, 2025

Rocket Pharmaceuticals Q3 Net Income USD -50.3 Million

THOMSON REUTERS
·
Nov 07, 2025

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

THOMSON REUTERS
·
Nov 07, 2025

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

Benzinga_recent_news
·
Nov 05, 2025

Rocket Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
Nov 03, 2025

Rocket Pharmaceuticals Inc. Officer John Militello Reports Disposal of Common Shares

Reuters
·
Oct 17, 2025

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Oct 15, 2025

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for KRESLADI™ Gene Therapy for Severe LAD-I; PDUFA Date Set for March 2026

Reuters
·
Oct 14, 2025

Rocket Pharmaceuticals Announces FDA Acceptance of Bla Resubmission of Kresladi™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

THOMSON REUTERS
·
Oct 14, 2025

Rocket Pharmaceuticals Inc - Pdufa Target Action Date Set for March 28, 2026

THOMSON REUTERS
·
Oct 14, 2025

Rocket Pharmaceuticals Inc - All Primary & Secondary Endpoints Met, Kresladi Well Tolerated

THOMSON REUTERS
·
Oct 14, 2025

Rocket Pharmaceuticals announces new equity compensation package for Chief Medical Officer

Reuters
·
Oct 11, 2025

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Oct 11, 2025

Rocket Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Peter Fong

Reuters
·
Oct 04, 2025

Leerink Partners Adjusts Rocket Pharmaceuticals Price Target to $7 From $9, Maintains Market Perform Rating

MT Newswires Live
·
Oct 04, 2025

Rocket Pharmaceuticals Is Maintained at Market Perform by Leerink Partners

Dow Jones
·
Oct 03, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet

Reuters
·
Oct 03, 2025